Alzheimer's disease (AD) and Parkinson's disease (PD) are the most prevalent
neurodegenerative diseases, affecting millions and costing billions each year in the United …

Mesenchymal stem cells (MSCs) have recently been considered a promising alternative
treatment for diverse immune disorders due to their unique biomedical potentials including …

There is increasing evidence for blood–brain barrier (BBB) alterations in Parkinson's
disease (PD), the second most common neurodegenerative disorder with rapidly rising …

Since its discovery in 2012, CRISPR Cas9 has been tried as a direct treatment approach to
correct the causative gene mutation and establish animal models in neurodegenerative …

Cell therapy is one of the newest therapeutic approaches for treating tissue destruction
diseases and replacing damaged parts in defective tissues. Among different cells …

Mutations in specific genes, including synuclein alpha (SNCA) that encodes the α-synuclein
protein, are known to be risk factors for sporadic Parkinson's disease (PD), as well as critical …

Neurological disorders are primarily diseases with sophisticated etiology that are always
refractory and recrudescent. The major obstruction to effective therapies for neurological …

CRISPR/Cas9 system exploits the concerted action of Cas9 nuclease and programmable
single guide RNA (sgRNA), and has been widely used for genome editing. The Cas9 …

Ischemic stroke is the leading cause of mortality and long-term disability worldwide.
Disruption of the blood–brain barrier (BBB) is a prominent pathophysiological mechanism …

In recent years, mesenchymal stromal cells (MSCs) have generated a lot of attention due to
their paracrine and immuno-modulatory properties. mesenchymal stromal cells derived from …